Updated follow‐up of BELLWAVE‐001: an open‐label, single‐arm, phase 1/2 study of the efficacy and safety of nemtabrutinib for the treatment of B‐cell malignancies.

Autor:	Eradat, H., Woyach, J., Flinn, I. W., Awan, F. T., Brander, D., Tees, M., Parikh, S. A., Phillips, T., Ghori, R., Paydar, I., Farooqui, M. Z. H., Byrd, J. C., Stephens, D. M.
Předmět:	BRUTON tyrosine kinase CHRONIC lymphocytic leukemia
Zdroj:	Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p565-567, 3p
Abstrakt:	Among pts with CLL/SLL, the median number of prior lines of therapy was 4 (range, 2-18), all pts received prior BTKi therapy, 27 (47%) received prior BTKi and BCL2i therapy, and 36 (63%) had C481S-mutated BTK. B Background: b Bruton tyrosine kinase inhibitors (BTKis) are standard of care for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), but resistance can develop, most commonly because of BTK mutations. AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Genentech, Genmab, Hutchison MediPharma, Iksuda Therapeutics, InnoCare Pharma, Janssen, Kite Pharma, MorphoSys, Myeloid Therapeutics, Novartis, Nurix Therapeutics, Pharmacyclics, Roche, Secura Bio, Servier Pharmaceuticals, Takeda, TG Therapeutics, Verastem, Vincerx Pharma, Xencor Research funding: Research Grants: All payments made to Sarah Cannon Research Institute, not to the physician. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text